I suspect that any revenue from treating dogs with DCVax would be insignificant and therefor not worth bringing up as an issue, as if there was something inappropriate. Instead, it may have been able to give them some initial early insights beyond mice trials that could make the difference of this company leaping into the billion or tens of billion valuation. Any potential revenue from the dog treatment (study) would have been peanuts.